Female Tg rasH2 (CB6F1/Jic-TgrasH2@Tac) mice were administered water once daily, water twice daily with 8 or 12 hours between doses, 1% sodium dodecyl sulfate in water (1% SDS) once daily, or 1% SDS twice daily with 12 hours between doses by oral gavage at volumes of 10 ml/kg/day for 28 or 29 consecutive days. A control group of mice received no treatment and no sham manipulation. There were no significant differences in body weight or food consumption between treated groups and untreated control mice. Mean weights of spleens, livers, and thymuses were lower than control values in most groups of mice subjected to gavage. Focal or multifocal loss of thymic cortical architecture was observed in 13 of 50 mice distributed among all groups (including naïve controls), however only in one instance was this finding suggestive of a precursor to neoplasia. This study demonstrated that Tg rasH2 mice can tolerate once or twice daily gavage dosing with water or vehicle containing 1% SDS. Loss of thymic cortical architecture was a common incidental finding in female Tg rasH2 mice.
INTRODUCTION
The Tg rasH2 mouse model has been proposed as a replacement for the 2-year mouse bioassay for the prediction of carcinogenic potential of pharmaceutical candidates in humans (International Conference on Harmonization, 1998; Yamamoto et al., 1998; Usui et al., 2001; Morton et al., 2002) . The Tg rasH2 mouse genome contains approximately 3 copies of the human c-Ha-ras gene with its own promoter (Tamaoki, 2001) . Overexpression of the ras p21 protein predisposes these mice to spontaneous and chemically induced neoplasia without mutations in the c-Ha-ras gene. This model is sensitive to genotoxic and nongenotoxic carcinogens following a 6-month dosing period (Yamamoto et al., 1998; Usui et al., 2001; Takaoka et al., 2003) . The overall incidence of spontaneous neoplasia in untreated Tg rasH2 mice is low until the mice exceed approximately 8-9 months of age.
In initial experimental studies with Tg rasH2 mice, test chemicals often were administered in food or water, however, it is preferable to administer some pharmaceutical agents by gavage. Twice daily dosing may be required to achieve desired exposures to some chemicals. The effects of repeated twice daily oral gavage in Tg rasH2 mice have not been described. In a previous 4-week range finding study conducted to support dose selection for a pivotal 6-month Tg rasH2 mouse carcinogenicity study, 10 control Tg rasH2 mice of each sex were administered vehicle consisting of 1% SDS, 0.5% methylcellulose, and 0.1% Tween 80 in water at a dose of 5 mL/kg twice daily (10 mL/kg/day) by gavage for 28 days. Body weights for control mice and treated mice of both sexes declined 8-10% by the end of the study. The mean body weight losses in control male and female mice averaged 2.0 g and 1.7 g, respectively, over the 4-week dosing period. Mean food consumption in control male mice declined 15% over the treatment period, but food consumption for female mice was similar during weeks 1 and 4. It was hypothesized that twice daily gavage dosing was not well tolerated by Tg rasH2 mice. These findings raised concerns that twice daily dosing by gavage using a vehicle containing 1% SDS for the duration of a 6-month Tg rasH2 mouse carcinogenicity study might not be feasible, and additional studies described in this report were undertaken to assess these concerns. This report describes studies to evaluate the effects of once and twice daily gavage dosing with a control vehicle containing 1% SDS following 28 or 29 days of dosing to female Tg rasH2 mice.
METHODS
Fifty barrier-reared specific-pathogen-free hemizygous female Tg rasH2 (CB6F1/Jic-TgrasH2@Tac) mice were obtained from Taconic (Germantown, NY). Female mice were selected because they were smaller and therefore potentially more sensitive than males to twice daily treatment by oral gavage. All mice were tested for the presence of the transgene prior to shipment from the vendor. The mice were 9 weeks of age at arrival, were acclimated for 12 days prior to the initiation of the experiment, and were 15 weeks of age at the end of the study. Mice were housed singly in polycarbonate cages with wire mesh lids and paper bedding (ALPHAdri, Shepherd Specialty Papers, Kalamazoo, MI), fed Purina Certified Rodent Diet #5002 (PMI Nutrition International, Richmond, IN) ad libitum, and given unlimited access to water purified by reverse osmosis in a conventional animal facility accredited by AAALAC, International. The animal room was maintained at 72 ± 5 • F with relative humidity between 30 and 70%, and lighting was provided 12 hours per day. All procedures were approved by the Institutional Animal Care and Use Committee.
Mice were assigned randomly by body weight to 1 of 6 groups as shown in Table 1 . Mice were administered water TOXICOLOGIC PATHOLOGY Water by gavage twice daily with 12 hours between doses 9 1% SDS by gavage once daily 9 1% SDS by gavage twice daily with 12 hours between doses once daily, water twice daily with 8 hours between doses, water twice daily with 12 hours between doses, 1% sodium dodecyl sulfate in water (1% SDS) once daily, or 1% SDS twice daily with 12 hours between doses by oral gavage using 22-gauge stainless steel gavage needles at a volume of 10 ml/kg/day for at least 28 consecutive days. All solutions were stored and administered at room temperature. An additional control group of Tg rasH2 mice received no treatment and no sham manipulation. Care was taken to handle the mice gently during treatment and observations. Animals were observed twice daily and detailed examinations were performed weekly 1-3 hours after treatment. Body weights were recorded prior to study, at weekly intervals throughout the study period, and immediately prior to necropsy. Food consumption was measured on study days 8, 15, and 22. One day after the last dose, mice were euthanized with 80% oxygen/20% carbon dioxide followed by exsanguination and necropsy. The adrenal glands, brain, heart, kidneys, liver, spleen, and thymus of each mouse were weighed, and organ to body weight ratios were calculated. Adrenal glands, brain, cecum, colon, duodenum, esophagus, heart, ileum, jejunum, kidneys, liver, lung, pancreas, skeletal muscle, spleen, stomach, thymus, thyroid, spinal cord, and mesenteric lymph node were collected in neutral buffered 10% formalin. Samples of esophagus, kidney, liver, spleen, stomach, and thymus from each mouse were embedded in paraffin, sectioned at 4-5 µm, stained with hematoxylin and eosin, and examined microscopically. Body weights and food consumption were analyzed using Dunnett's test. Organ weights were analyzed by analysis of variance. Results were considered positive when p ≤ 0.05. Groups treated by gavage were compared to mice receiving no treatment.
RESULTS

Body Weights and Food Consumption:
There were no statistically significant differences in mean body weights throughout the study (Figure 1 ). Tg rasH2 mice in all groups, including the untreated control mice, did not gain weight during the dosing period, and mean body weights after 4 weeks of dosing were slightly lower than mean body weights on the first day of dosing.
Food consumption was measured on days 8, 15, and 22 ( Figure 2 ). No meaningful differences in food consumption were observed. Food consumption was lower in all groups on days 15 and 22 than on day 8.
Necropsy Observations: All mice survived for the full 28or 29-day dosing period. No gross necropsy observations were related to treatment. One untreated control mouse had FIGURE 1.-Mean body weights of Tg rasH2 mice at study days 1 and 28. There were no statistically significant differences in body weights between treated and untreated mice using Dunnett's test. QD = Once daily. BID = Twice daily. a 1-cm spherical ulcerated cutaneous mass over the right hip. The only other gross observation was incidental black discoloration (pigmentation) of the spleens in 10 mice from multiple groups including 2 untreated control mice.
Organ Weights: Mean absolute organ weights and mean organ weight to body weight ratios are provided in Table 2 . Spleen weights and spleen to body weight ratios were significantly lower in all groups of mice subjected to gavage than in untreated mice ( p < 0.05). The mean thymic weights for mice administered water or 1% SDS once daily were 77% and 73% of the untreated control mean, respectively, while the mean thymic weights of mice treated twice daily with water or 1% SDS were 54-58% of the untreated control mean. Only mice treated twice daily had thymic weights that were significantly lower than the thymic weights of untreated mice. Thymus to body weight ratios were significantly lower in mice treated twice daily with either water or 1% SDS and in mice treated once daily with 1% SDS than in untreated mice. Mean liver weights in all mice treated once or twice daily were approximately 0.2 g lower than the mean liver weight of untreated mice, but these differences were Weight ( statistically significant ( p < 0.05) only in mice administered 1% SDS once or twice daily. Liver to body weight ratios were significantly lower than untreated control values in all mice except those administered water twice daily with 8 hours between doses. No treatment-related differences in adrenal, brain, heart, or kidney weights were observed. Microscopic Observations: The incidences of microscopic findings in thymus, spleen, and liver are listed in Table 3 . Three mice had mild degeneration of esophageal muscle compatible with mild injury during the gavage procedure. No lesions were seen in stomachs. Administration of 1% SDS caused no morphologic changes in esophagus or stomach.
Thirteen mice distributed among all groups (including 1 naïve control mouse) had microscopic findings in the thymus consisting of focal to locally extensive loss of cortical architecture and replacement of the cortex by a mixture of large and small lymphocytes and thymic epithelial and stromal cells that resembled the normal thymic medulla (Figure 3 ). Most affected mice had some areas of thymus with normal architecture. In some affected mice, there was hyperplasia of thymic epithelial cells and loss of most lymphocytes. In 1 untreated mouse, closely packed large lymphocytes infiltrated the cortex and medulla and obscured the normal thymic medullary and cortical architecture. The incidence of loss of thymic cortical architecture was highest in mice administered water twice daily with 8 hours between doses and mice administered 1% SDS twice daily. The mean weight of affected thymuses was 25% lower than mean weight of unaffected thymuses (0.033 g vs 0.042 g). Lesions observed in the spleen were not related to treatment and included depletion of lymphocytes, decreased cellularity of the red pulp, focal deposits of melanin with or without fibrosis corresponding to splenic pigmentation seen at necropsy, and hemangiosarcoma in one mouse.
Single or multiple microscopic foci of hepatic necrosis were located randomly within the liver in 1 or 2 mice from all treatment groups including the untreated control group. Necrotic foci contained infiltrates of macrophages and fewer granulocytes. These minimal lesions were considered spontaneous lesions and were unrelated to treatment.
One untreated mouse developed an inverted squamous papilloma of the skin during the treatment period that was observed at necropsy.
DISCUSSION
This study demonstrated that female Tg rasH2 mice can tolerate twice daily dosing with water or vehicle containing 1% SDS at 10 ml/kg/day (BID doses divided into 2 doses of 5 ml/kg/day) for 4 weeks without significant adverse effects related to dosing if the mice are handled with care. Body weights and food consumption were comparable between untreated mice and those treated by gavage once or twice daily.
Lower thymic and splenic weights in mice treated once or twice daily suggested that these mice may have experienced greater stress than untreated mice, however, the lack of changes in body weight, food consumption, and adrenal weights did not support a conclusion that mice dosed by gavage were severely stressed or adversely affected by the gavage procedure. Decreased liver weights in mice treated by gavage appeared to be related to the gavage procedure rather than to the frequency of dosing or the material administered, since mice treated with water or 1% SDS either once or twice daily had similar mean decreases in liver weights. The cause of the liver weight changes was not determined. In the absence of treatment-related microscopic liver lesions or any other explanation for decreased liver weights, the decreases in liver weights were not considered adverse. Microscopic findings in thymus, spleen, kidney, liver, and skin were unrelated to treatment since similar findings were observed in untreated Tg rasH2 control mice or findings occurred only in 1 or 2 animals.
Focal or multifocal loss of thymic cortical architecture was found 13 of 50 female Tg rasH2 mice, or 26% of all animals. Focal areas of thymic epithelial hyperplasia and lymphocyte depletion were associated with loss of cortical architecture in some mice. Affected thymuses had a lower mean weight than histologically normal thymuses. Thymic atypical hyperplasia has been described in p53+/− mice and B6C3F1 mice. One description of thymic atypical hyperplasia which closely resembled most thymic changes seen in our study used the term medullary hyperplasia to describe the altered appearance of the medulla and cortex (Ward et al., 1999) . In p53+/− mice and B6C3F1 mice treated with phenophthalein however, atypical hyperplasia in p53+/− and B6C3F1 was considered a preneoplastic proliferative change that preceded overt lymphoma (Dunnick et al., 1997; Dunnick and Hailey, 1996; Ward et al., 1999) . Because only 1 mouse in our study (an untreated control mouse) demonstrated loss of cortical architecture associated with infiltration of the thymus by large lymphocytes (considered a premalignant lesion), changes in thymic cortical architecture and associated loss of thymic mass were interpreted to be a common incidental lesion in female Tg rasH2 mice that in most cases did not appear to be a precursor to malignant lymphoma.
Since Tg rasH2 mice are prone to develop spontaneous and chemically induced papillomas and carcinomas of the forestomach and skin (Yamamoto et al., 1998; Usui et al., 2001) , any irritation of the forestomach by SDS could enhance the formation of forestomach neoplasia in these mice. Sodium dodecyl sulfate is a surfactant that, at high doses, may cause irritation, ulceration, and hemorrhage of the forestomach in rats (United Nations Environment Programme, 1997) . Other irritating nongenotoxic solvents have been shown to produce increased epithelial proliferation and epithelial neoplasms of the forestomach in rats and mice (Kroes and Webster, 1986; Ito et al., 1993; Green et al., 2002; Kaneko et al., 2002) . We determined that 1% SDS caused no histological evidence of inflammation or damage to the esophagus and forestomach, and therefore could likely be used as a vehicle in 6-month Tg rasH2 carcinogenicity studies without concern that the 1% SDS would enhance the formation of forestomach neoplasms. Therefore, 1% SDS may be added to oral dosing formulations for animals to increase the solu-bility of chemicals in aqueous media without increasing the incidence of esophageal or forestomach lesions.
This study demonstrated that there were alterations in organ weight findings in female Tg rasH2 mice treated twice daily with water or 1% SDS by oral gavage. However, these changes were not associated with alterations in body weight, food consumption, or gross and histological changes, and are therefore not interpreted to be toxicologically significant. In addition, 1% SDS did not appear to increase the incidence of papillomas and carcinomas of the forestomach of these transgenic mice. When appropriate care is taken during dosing of Tg rasH2 mice by oral gavage, stress-related histopathological lesions and decreases in body weight related to the gavage procedure can be avoided.
